178 related articles for article (PubMed ID: 32185579)
21. Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
Oyaga-Iriarte E; Insausti A; Sayar O; Aldaz A
J Pharmacol Sci; 2019 May; 140(1):20-25. PubMed ID: 31105026
[TBL] [Abstract][Full Text] [Related]
22. Effects of inflammation on irinotecan pharmacokinetics and development of a best-fit PK model.
Chityala PK; Wu L; Chow DS; Ghose R
Chem Biol Interact; 2020 Jan; 316():108933. PubMed ID: 31870839
[TBL] [Abstract][Full Text] [Related]
23. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
Allegrini G; Di Paolo A; Cerri E; Cupini S; Amatori F; Masi G; Danesi R; Marcucci L; Bocci G; Del Tacca M; Falcone A
Cancer Chemother Pharmacol; 2006 Nov; 58(5):585-93. PubMed ID: 16680463
[TBL] [Abstract][Full Text] [Related]
24. A validated UPLC-MS/MS method to determine free and total irinotecan and its two metabolites in human plasma after intravenous administration of irinotecan hydrochloride liposome injection.
Zhuang Q; Liu X; Sun Z; Wang H; Jiang J
J Pharm Biomed Anal; 2019 Jun; 170():112-123. PubMed ID: 30921645
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors.
Schmidt KT; Huitema ADR; Dorlo TPC; Peer CJ; Cordes LM; Sciuto L; Wroblewski S; Pommier Y; Madan RA; Thomas A; Figg WD
Cancer Chemother Pharmacol; 2020 Oct; 86(4):475-486. PubMed ID: 32897402
[TBL] [Abstract][Full Text] [Related]
26. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Rothenberg ML; Kuhn JG; Schaaf LJ; Rodriguez GI; Eckhardt SG; Villalona-Calero MA; Rinaldi DA; Hammond LA; Hodges S; Sharma A; Elfring GL; Petit RG; Locker PK; Miller LL; von Hoff DD
Ann Oncol; 2001 Nov; 12(11):1631-41. PubMed ID: 11822765
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
Gupta E; Mick R; Ramirez J; Wang X; Lestingi TM; Vokes EE; Ratain MJ
J Clin Oncol; 1997 Apr; 15(4):1502-10. PubMed ID: 9193346
[TBL] [Abstract][Full Text] [Related]
28. Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients.
Bao X; Wu J; Kim S; LoRusso P; Li J
J Clin Pharmacol; 2019 Jan; 59(1):20-34. PubMed ID: 30052267
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
[TBL] [Abstract][Full Text] [Related]
30. Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide.
Sloan JA; Atherton P; Reid J; Pitot HC; Erlichman C; Schaaf L
Cancer Chemother Pharmacol; 2001 Sep; 48(3):241-9. PubMed ID: 11592347
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Goetz MP; Erlichman C; Windebank AJ; Reid JM; Sloan JA; Atherton P; Adjei AA; Rubin J; Pitot H; Galanis E; Ames MM; Goldberg RM
J Clin Oncol; 2003 Oct; 21(20):3761-9. PubMed ID: 12963697
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic study of two infusion schedules of irinotecan combined with cisplatin in patients with advanced gastric cancer.
Fujitani K; Tsujinaka T; Hirao M
Oncology; 2003; 64(2):111-5. PubMed ID: 12566907
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
Klein CE; Gupta E; Reid JM; Atherton PJ; Sloan JA; Pitot HC; Ratain MJ; Kastrissios H
Clin Pharmacol Ther; 2002 Dec; 72(6):638-47. PubMed ID: 12496745
[TBL] [Abstract][Full Text] [Related]
34. CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.
Saltz L; Shimada Y; Khayat D
Eur J Cancer; 1996; 32A Suppl 3():S24-31. PubMed ID: 8943662
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors.
Kimura T; Kashiwase S; Makimoto A; Kumagai M; Taga T; Ishida Y; Ida K; Nagatoshi Y; Mugishima H; Kaneko M; Barrett JS
Int J Clin Pharmacol Ther; 2010 May; 48(5):327-34. PubMed ID: 20420789
[TBL] [Abstract][Full Text] [Related]
36. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
Mick R; Gupta E; Vokes EE; Ratain MJ
J Clin Oncol; 1996 Jul; 14(7):2012-9. PubMed ID: 8683231
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Goldberg RM; Kaufmann SH; Atherton P; Sloan JA; Adjei AA; Pitot HC; Alberts SR; Rubin J; Miller LL; Erlichman C
Ann Oncol; 2002 Oct; 13(10):1674-80. PubMed ID: 12377659
[TBL] [Abstract][Full Text] [Related]
38. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
39. Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.
Sy SKB; Chia YL; Gordi T; Hoch U; Eldon MA
Cancer Chemother Pharmacol; 2018 May; 81(5):897-909. PubMed ID: 29564497
[TBL] [Abstract][Full Text] [Related]
40. Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
Mathijssen RH; van Alphen RJ; de Jonge MJ; Verweij J; de Bruijn P; Loos WJ; Nooter K; Vernillet L; Stoter G; Sparreboom A
Anticancer Drugs; 1999 Jan; 10(1):9-16. PubMed ID: 10194542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
